Cited by 21Cannabis and Cannabinoid ResearchSubstance Abuse Treatment and OutcomesForensic Toxicology and Drug Analysis

Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006–2015

Open access
Maloney-Hall, Bridget, Wallingford, Sarah C., Konefal, Sarah, Young, Matthew M.·2020·Health Promotion and Chronic Disease Prevention in Canada

Abstract

Introduction: Given the recent and impending changes to the legal status of nonmedical cannabis use in Canada, understanding the effects of cannabis use on the health care system is important for evaluating the impact of policy change. The aim of this study was to examine pre-legalization trends in hospitalizations for mental and behavioural disorders due to the use of cannabis, according to demographics factors and clinical conditions. Methods: We assessed the total number of inpatient hospitalizations for psychiatric conditions with a primary diagnosis of a mental or behavioural disorder due to cannabis use (ICD-10-CA code F12) from the Hospital Mental Health Database for ten years spanning 2006 to 2015, inclusive. We included hospitalizations from all provinces and territories except Quebec. Rates (per 100 000 persons) and relative proportions of hospitalizations by clinical condition, age group, sex and year are reported. Results: Between 2006 and 2015, the rate of cannabis-related hospitalizations in Canada doubled. Of special note, however, is that hospitalizations during this time period for those with the clinical condition code "mental and behavioural disorders due to use of cannabinoids, psychotic disorder" (F12.5) tripled, accounting for almost half (48%) of all cannabis-related hospitalizations in 2015. Conclusion: Further research is required to investigate the reasons for the increase in hospitalizations for cannabis-related psychotic disorder. The introduction of high-potency cannabinoid products and synthetic cannabinoids into the illicit market are considered as possible factors.

Integrity signals

Registry

Crossref · 10.24095/hpcdp.40.5/6.06

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The rate of cannabis-related hospitalizations for an ICD-10 mental or behavioural disorder due to cannabis more than doubled between 2006 and 2015 (from 2.11 to 5.18 per 100 000).

    “Maloney‐Hall et al. [41], for example, found that the rate of cannabis‐related hospitalizations for an ICD‐10 mental or behavioural disorder due to cannabis more than doubled between 2006 and 2015 (from 2.11 in 2006 to 5.18 per 100 000 in 2015).”
  • The increase in cannabis-related hospitalizations for mental or behavioural disorder was most marked in people aged 15-24 years (a 19-fold increase between 2006 and 2015).

    “The increase was most marked in people aged 15–24 years (a 19‐fold increase between 2006 and 2015).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Maloney-Hall, B., Wallingford, S. C., Konefal, S., & Young, M. M.
Affiliations
  • Canadian Centre on Substance Use and Addiction, Ottawa, Ontario, Canada
  • Ottawa Public Health (CA)
  • Canadian Centre on Substance Use and Addiction (CA)
Corresponding author
Young, Matthew M.
Venue
Health Promotion and Chronic Disease Prevention in Canada
Published
2020-06
Volume
40
Issue
5/6
Pages
176-183
ISSN
2368-738X (ISSN-L)
OpenAlex
W3034463523
Cited by
21
References
4
Citations by year
2026: 1 · 2024: 7 · 2023: 5 · 2022: 6 · 2021: 1 · 2020: 1
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Health Promotion and Chronic Disease Prevention in Canada (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • HRB National Drugs Library (Health Research Board) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords
cannabis use, psychosis, cannabis legalization, hospitalization trends, synthetic cannabinoids, mental health service utilization, Canada
MeSH terms
Synthetic Drugs, Adult, Age Factors, Canada, Cannabinoids, Marijuana Abuse, Female, Hospitalization, Humans, Male, Mental Health, Psychiatric Status Rating Scales, Psychoses, Substance-Induced, Risk Factors, Sex Factors, Prevalence, International Classification of Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review